<p>Inspire Investing LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第三季度将其在 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）的持股增加了 125.9%。该机构投资者在此期间购买了额外的 40,386 股后，持有该生物技术公司 72,459 股股票。根据其最近向证券交易委员会（SEC）提交的文件，Inspire Investing LLC 在 Exelixis 的持股价值为 2,993,000 美元。</p>
<ul>
<li>3 只适合软着陆的股票，如果有的话</li>
</ul>
<p>其他对冲基金和机构投资者最近也增加或减少了在该公司的股份。Byrne Asset Management LLC 在第二季度将其在 Exelixis 的股份增加了 129.0%。Byrne Asset Management LLC 现在拥有 710 股该生物技术公司的股票，价值 31,000 美元，此前在上个季度又购买了 400 股。Luminist Capital LLC 在第二季度将其在 Exelixis 的股份增加了 2,740.0%。Luminist Capital LLC 现在拥有 710 股该生物技术公司的股票，价值 31,000 美元，此前在上个季度又购买了 685 股。Family Legacy Financial Solutions LLC 在第二季度购买了 Exelixis 的新股份，价值约 33,000 美元。Steph &amp; Co. 在第二季度购买了 Exelixis 的新股份，价值约 44,000 美元。最后，Hantz Financial Services Inc. 在第二季度将其在 Exelixis 的股份增加了 940.4%。Hantz Financial Services Inc. 现在拥有 1,134 股该生物技术公司的股票，价值 50,000 美元，此前在上个季度又购买了 1,025 股。目前，85.27% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Exelixis 股票上涨 0.1%</h2>
<p>EXEL 股票周四开盘价为 46.64 美元。Exelixis, Inc. 的 52 周低点为 31.90 美元，52 周高点为 49.62 美元。该公司的市值为 125 亿美元，市盈率为 19.68，市盈增长比率为 0.84，贝塔值为 0.40。公司的 50 日简单移动平均线为 41.53 美元，200 日简单移动平均线为 40.88 美元。</p>
<ul>
<li>3 只强劲的生物技术股票值得关注，随着行业接近突破</li>
</ul>
<p>Exelixis（NASDAQ:EXEL - 获取免费报告）最近于 11 月 4 日星期二发布了季度财报。该生物技术公司报告本季度每股收益为 0.78 美元，超出分析师一致预期的 0.68 美元，超出幅度为 0.10 美元。Exelixis 的股本回报率为 31.06%，净利润率为 29.63%。该公司本季度的收入为 5.9776 亿美元，而分析师预期为 5.9004 亿美元。去年同期，该公司每股收益为 0.47 美元。Exelixis 本季度的收入较去年同期增长了 10.8%。分析师预计 Exelixis, Inc. 本财年将发布 2.04 美元的每股收益。</p>
<h2>内部人士下注</h2>
<p>在其他 Exelixis 的新闻中，执行副总裁 Dana Aftab 于 11 月 11 日星期二出售了 48,383 股公司的股票。股票以平均价格 42.50 美元出售，总交易额为 2,056,277.50 美元。交易完成后，该执行副总裁直接持有 664,778 股公司股票，价值约 28,253,065 美元。这代表其持股减少了 6.78%。该交易已在向 SEC 提交的法律文件中披露，相关文件可通过此超链接访问。此外，董事 Stelios Papadopoulos 于 11 月 12 日星期三出售了 100,000 股 Exelixis 股票。股票以平均价格 43.55 美元出售，总交易额为 4,355,000.00 美元。交易完成后，该董事持有 1,189,228 股公司股票，价值约 51,790,879.40 美元。此交易代表其持股减少了 7.76%。有关此交易的更多细节可在官方 SEC 披露中找到。在上个季度，内部人士共出售了价值 10,490,600 美元的 245,235 股公司股票。公司内部人士持有 2.82% 的公司股票。</p>
<h2>分析师评级变动</h2>
<ul>
<li>现在投资的 7 只最佳癌症股票</li>
</ul>
<p>几位股票研究分析师最近对该股票发表了评论。HC Wainwright 在 11 月 5 日星期三的研究报告中将 Exelixis 的目标价从 46.00 美元上调至 49.00 美元，并给予该股票 &#34;买入&#34; 评级。瑞银集团在 11 月 6 日星期四的研究报告中将 Exelixis 的目标价从 35.00 美元上调至 40.00 美元，并给予该股票 &#34;中性&#34; 评级。Leerink Partners 在 10 月 21 日星期二的报告中将 Exelixis 的评级从 &#34;市场表现&#34; 上调至 &#34;跑赢大盘&#34;，并设定了 48.00 美元的目标价。富国银行在 10 月 21 日星期二的报告中将 Exelixis 的目标价从 36.00 美元下调至 30.00 美元，并为该公司设定了 &#34;持平&#34; 评级。最后，TD Cowen 在 11 月 5 日星期三的研究报告中将 Exelixis 的目标价从 44.00 美元上调至 51.00 美元，并给予该公司 &#34;买入&#34; 评级。一位投资分析师对该股票给予了强烈买入评级，十四位分析师给予了买入评级，十一位分析师给予了持有评级。根据 MarketBeat.com 的数据，Exelixis 的共识评级为 &#34;适度买入&#34;，共识目标价为 45.74 美元。</p>
<p><strong>查看我们最新的 EXEL 股票分析</strong></p>
<h2>关于 Exelixis</h2>
<p>（免费报告）</p>
<p>Exelixis, Inc. 是一家生物技术公司，专注于小分子疗法的发现、开发和商业化，主要用于癌症治疗。该公司基于利用模式生物遗传学和高通量筛选的平台，专注于调节肿瘤生长和转移相关的关键信号通路的激酶抑制剂的研究。Exelixis 的转化研究方法旨在将新化合物从早期发现推进到临床开发和监管批准。</p>
<p>该公司最知名的产品包括 CABOMETYX®（cabozantinib），已获批准用于治疗晚期肾细胞癌和肝细胞癌，以及 COMETRIQ®（cabozantinib），用于治疗转移性髓样甲状腺癌。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们认为比 Exelixis 更好的股票</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉 AI，这将是下一个重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA"/></p>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Exelixis 吗？</h2>
<p>在考虑 Exelixis 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Exelixis 并不在名单上。</p>
<p>虽然 Exelixis 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

伊克力西斯

<p>Inspire Investing LLC 在第三季度将其在伊克力西斯的持股增加了 125.9%，目前拥有 72,459 股，价值 2,993,000 美元。其他机构投资者也调整了他们的持股。伊克力西斯报告第三季度每股收益为 0.78 美元，超出预期，收入同比增长 10.8%。内部人士在上个季度出售了 245,235 股，价值 10,490,600 美元。分析师的评级不一，有些分析师上调了目标价格</p>

<p>Inspire Investing LLC boosted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 125.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,459 shares of the biotechnology company's stock after buying an additional 40,386 shares during the period. Inspire Investing LLC's holdings in Exelixis were worth $2,993,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Inspire Investing LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第三季度将其在 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）的持股增加了 125.9%。该机构投资者在此期间购买了额外的 40,386 股后，持有该生物技术公司 72,459 股股票。根据其最近向证券交易委员会（SEC）提交的文件，Inspire Investing LLC 在 Exelixis 的持股价值为 2,993,000 美元。</p>
</div><ul>
<li>3 Stocks to Buy for a Soft Landing, If There Is One</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只适合软着陆的股票，如果有的话</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Byrne Asset Management LLC grew its stake in shares of Exelixis by 129.0% during the second quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 400 shares during the last quarter. Luminist Capital LLC boosted its stake in Exelixis by 2,740.0% in the 2nd quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 685 shares in the last quarter. Family Legacy Financial Solutions LLC purchased a new stake in Exelixis during the 2nd quarter worth approximately $33,000. Steph &amp; Co. purchased a new stake in Exelixis during the 2nd quarter worth approximately $44,000. Finally, Hantz Financial Services Inc. increased its stake in Exelixis by 940.4% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,134 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 1,025 shares in the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也增加或减少了在该公司的股份。Byrne Asset Management LLC 在第二季度将其在 Exelixis 的股份增加了 129.0%。Byrne Asset Management LLC 现在拥有 710 股该生物技术公司的股票，价值 31,000 美元，此前在上个季度又购买了 400 股。Luminist Capital LLC 在第二季度将其在 Exelixis 的股份增加了 2,740.0%。Luminist Capital LLC 现在拥有 710 股该生物技术公司的股票，价值 31,000 美元，此前在上个季度又购买了 685 股。Family Legacy Financial Solutions LLC 在第二季度购买了 Exelixis 的新股份，价值约 33,000 美元。Steph &amp; Co. 在第二季度购买了 Exelixis 的新股份，价值约 44,000 美元。最后，Hantz Financial Services Inc. 在第二季度将其在 Exelixis 的股份增加了 940.4%。Hantz Financial Services Inc. 现在拥有 1,134 股该生物技术公司的股票，价值 50,000 美元，此前在上个季度又购买了 1,025 股。目前，85.27% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Exelixis Stock Up 0.1%</h2>
<div class="lb-trans"><h2>Exelixis 股票上涨 0.1%</h2>
</div><p>EXEL stock opened at $46.64 on Thursday. Exelixis, Inc. has a 52-week low of $31.90 and a 52-week high of $49.62. The firm has a market cap of $12.50 billion, a P/E ratio of 19.68, a PEG ratio of 0.84 and a beta of 0.40. The company's 50-day simple moving average is $41.53 and its 200-day simple moving average is $40.88.</p>
<div class="lb-trans"><p>EXEL 股票周四开盘价为 46.64 美元。Exelixis, Inc. 的 52 周低点为 31.90 美元，52 周高点为 49.62 美元。该公司的市值为 125 亿美元，市盈率为 19.68，市盈增长比率为 0.84，贝塔值为 0.40。公司的 50 日简单移动平均线为 41.53 美元，200 日简单移动平均线为 40.88 美元。</p>
</div><ul>
<li>3 Strong Biotech Performers To Watch As Sector Nears Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只强劲的生物技术股票值得关注，随着行业接近突破</li>
</ul>
</div><p>Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.68 by $0.10. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The company had revenue of $597.76 million during the quarter, compared to analysts' expectations of $590.04 million. During the same quarter in the prior year, the firm posted $0.47 EPS. Exelixis's quarterly revenue was up 10.8% compared to the same quarter last year. On average, analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Exelixis（NASDAQ:EXEL - 获取免费报告）最近于 11 月 4 日星期二发布了季度财报。该生物技术公司报告本季度每股收益为 0.78 美元，超出分析师一致预期的 0.68 美元，超出幅度为 0.10 美元。Exelixis 的股本回报率为 31.06%，净利润率为 29.63%。该公司本季度的收入为 5.9776 亿美元，而分析师预期为 5.9004 亿美元。去年同期，该公司每股收益为 0.47 美元。Exelixis 本季度的收入较去年同期增长了 10.8%。分析师预计 Exelixis, Inc. 本财年将发布 2.04 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Exelixis news, EVP Dana Aftab sold 48,383 shares of the company's stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $42.50, for a total transaction of $2,056,277.50. Following the completion of the transaction, the executive vice president directly owned 664,778 shares in the company, valued at approximately $28,253,065. This represents a 6.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Stelios Papadopoulos sold 100,000 shares of Exelixis stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the completion of the sale, the director owned 1,189,228 shares in the company, valued at approximately $51,790,879.40. This trade represents a 7.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 245,235 shares of company stock worth $10,490,600. Corporate insiders own 2.82% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Exelixis 的新闻中，执行副总裁 Dana Aftab 于 11 月 11 日星期二出售了 48,383 股公司的股票。股票以平均价格 42.50 美元出售，总交易额为 2,056,277.50 美元。交易完成后，该执行副总裁直接持有 664,778 股公司股票，价值约 28,253,065 美元。这代表其持股减少了 6.78%。该交易已在向 SEC 提交的法律文件中披露，相关文件可通过此超链接访问。此外，董事 Stelios Papadopoulos 于 11 月 12 日星期三出售了 100,000 股 Exelixis 股票。股票以平均价格 43.55 美元出售，总交易额为 4,355,000.00 美元。交易完成后，该董事持有 1,189,228 股公司股票，价值约 51,790,879.40 美元。此交易代表其持股减少了 7.76%。有关此交易的更多细节可在官方 SEC 披露中找到。在上个季度，内部人士共出售了价值 10,490,600 美元的 245,235 股公司股票。公司内部人士持有 2.82% 的公司股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>7 Best Cancer Stocks to Invest in Now</li>
</ul>
<div class="lb-trans"><ul>
<li>现在投资的 7 只最佳癌症股票</li>
</ul>
</div><p>Several equities research analysts have recently commented on the stock. HC Wainwright lifted their price objective on shares of Exelixis from $46.00 to $49.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, November 5th. UBS Group lifted their price target on Exelixis from $35.00 to $40.00 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, November 6th. Leerink Partners raised Exelixis from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $48.00 price objective on the stock in a report on Tuesday, October 21st. Wells Fargo &amp; Company decreased their target price on Exelixis from $36.00 to $30.00 and set an &#34;equal weight&#34; rating for the company in a report on Tuesday, October 21st. Finally, TD Cowen upped their target price on Exelixis from $44.00 to $51.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eleven have assigned a Hold rating to the stock. According to data from MarketBeat.com, Exelixis has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $45.74.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该股票发表了评论。HC Wainwright 在 11 月 5 日星期三的研究报告中将 Exelixis 的目标价从 46.00 美元上调至 49.00 美元，并给予该股票 &#34;买入&#34; 评级。瑞银集团在 11 月 6 日星期四的研究报告中将 Exelixis 的目标价从 35.00 美元上调至 40.00 美元，并给予该股票 &#34;中性&#34; 评级。Leerink Partners 在 10 月 21 日星期二的报告中将 Exelixis 的评级从 &#34;市场表现&#34; 上调至 &#34;跑赢大盘&#34;，并设定了 48.00 美元的目标价。富国银行在 10 月 21 日星期二的报告中将 Exelixis 的目标价从 36.00 美元下调至 30.00 美元，并为该公司设定了 &#34;持平&#34; 评级。最后，TD Cowen 在 11 月 5 日星期三的研究报告中将 Exelixis 的目标价从 44.00 美元上调至 51.00 美元，并给予该公司 &#34;买入&#34; 评级。一位投资分析师对该股票给予了强烈买入评级，十四位分析师给予了买入评级，十一位分析师给予了持有评级。根据 MarketBeat.com 的数据，Exelixis 的共识评级为 &#34;适度买入&#34;，共识目标价为 45.74 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on EXEL</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 EXEL 股票分析</strong></p>
</div><h2>About Exelixis</h2>
<div class="lb-trans"><h2>关于 Exelixis</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.</p>
<div class="lb-trans"><p>Exelixis, Inc. 是一家生物技术公司，专注于小分子疗法的发现、开发和商业化，主要用于癌症治疗。该公司基于利用模式生物遗传学和高通量筛选的平台，专注于调节肿瘤生长和转移相关的关键信号通路的激酶抑制剂的研究。Exelixis 的转化研究方法旨在将新化合物从早期发现推进到临床开发和监管批准。</p>
</div><p>The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.</p>
<div class="lb-trans"><p>该公司最知名的产品包括 CABOMETYX®（cabozantinib），已获批准用于治疗晚期肾细胞癌和肝细胞癌，以及 COMETRIQ®（cabozantinib），用于治疗转移性髓样甲状腺癌。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Exelixis</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Exelixis 更好的股票</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉 AI，这将是下一个重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=EXEL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Exelixis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Exelixis 吗？</h2>
</div><p>Before you consider Exelixis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Exelixis 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Exelixis 并不在名单上。</p>
</div><p>While Exelixis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Exelixis 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

伊克力西斯公司 $EXEL 的股票被 Inspire Investing LLC 购入